CClinicalTrials.gg
CompletedNCT05125341Updated Jul 5, 2022

Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

An observational study in Paroxysmal Nocturnal Hemoglobinuria, Natural History Study, sponsored by CARE Pharma Shanghai Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-05.

Sponsored by CARE Pharma Shanghai Ltd. · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
67
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.

This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months.

The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria, Natural History Study
03

In context

Hemoglobinuria

107 studies on the registry are indexed under Hemoglobinuria; 10 are open to participants now.

This study's enrollment of 67 is close to the median of 64 across 16 observational studies indexed under Hemoglobinuria.

Browse Hemoglobinuria studies →

Lead sponsor

CARE Pharma Shanghai Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in China

Inclusion criteria

  1. Meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria;
  2. Age ≥ 18 years old;
  3. PNH clone size of granulocytes or monocytes (CD59 or Flaer) ≥ 10%;
  4. LDH≥1.5 ULN;
  5. Accompanied by at least one PNH-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction;
  6. Transfusion-dependent PNH patients;
  7. There are at least 6 months consecutive data of diagnosis and treatment after the data collection time point;
  8. Patients agreed to participate in the study by signing informed consent or giving oral informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients are under the treatment of the C1/C3/C5 complement inhibitors currently or in the past;
  2. Patients have received bone marrow transplantation;
  3. platelet count \<30*10 9/L or absolute neutrophil count \<0.5*10 9/L;
  4. Patients have clinically significant heart, liver, or lung diseases, or have related medical history.
  5. Patients have comorbidities of rheumatoid disease, HIV infection, active HBV infection, HCV infection and other diseases that affect the body's immune function;
  6. Severe missing data in the records of diagnosis and treatment after the data collection time point;
  7. Other patients who are not suitable to participate in the study.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
67 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. the mean change of LDH

    the mean change of LDH over 6 months

    Time frame: 6 months

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05125341
Lead sponsor
CARE Pharma Shanghai Ltd.
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Nov 25, 2021
Primary completion
Mar 16, 2022
Completion
Apr 30, 2022
Last update
Jul 5, 2022

Study contacts

Bing Han, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion